0000899243-19-016240.txt : 20190610
0000899243-19-016240.hdr.sgml : 20190610
20190610181619
ACCESSION NUMBER: 0000899243-19-016240
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190610
FILED AS OF DATE: 20190610
DATE AS OF CHANGE: 20190610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PDL BIOPHARMA, INC.
CENTRAL INDEX KEY: 0000882104
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36754
FILM NUMBER: 19889552
BUSINESS ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
BUSINESS PHONE: 775-832-8500
MAIL ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
FORMER NAME:
FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE
DATE OF NAME CHANGE: 19930328
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evofem Biosciences, Inc.
CENTRAL INDEX KEY: 0001618835
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208527075
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 550-1900
MAIL ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Neothetics, Inc.
DATE OF NAME CHANGE: 20140905
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-10
0
0001618835
Evofem Biosciences, Inc.
EVFM
0000882104
PDL BIOPHARMA, INC.
932 SOUTHWOOD BOULEVARD
INCLINE VILLAGE
NV
89451
0
0
1
0
Common Stock
2019-06-10
4
P
0
6666667
4.50
A
13333334
D
Warrants (Right to Buy)
6.38
2019-06-10
4
A
0
1666667
A
2019-12-10
2026-06-10
Common Stock
1666667
1666667
D
Pursuant to that certain Securities Purchase Agreement, dated as of April 10, 2019, by and among the Issuer, the Reporting Person and the other parties thereto, on June 10, 2019, the Reporting Person purchased 6,666,667 shares of Common Stock of the Issuer, at a price of $4.50 per share, and received warrants to purchase up to an additional 1,666,667 shares of Common Stock for an aggregate purchase price of approximately $30.0 million.
/s/ Peter S. Garcia, Chief Financial Officer of PDL BioPhram, Inc.
2019-06-10